Klin Farmakol Farm. 2005;19(3):142-145

Utilization of hypolipidaemics in Czech Republic between 1989 and 2003

Romana Pavelková, Mgr. Lucie Sobolová, Karel Urbánek

Ústav farmakologie LF UP a FN Olomouc

Hypolipidaemics have been used in the Czech Republic since the late 1970s. Fibrates were preferred in that period. An important event was the approval of the first statin – lovastatin. The aim of this study was to describe the utilization of hypolipidaemics in the period of 1989 to 2003. Data on hypolipidaemic drugs utilization were obtained from the database of the State Institute for Drug Control. Utilization was expressed in defined daily doses (DDD) according to the ATC/DDD system valid in 2004; expenditures were measured in Czech crowns (CZK). Utilization was expressed in relative values – DDD per 1,000 inhabitants per day (DID). The utilization of fibrates and statins in the followed period increased from 0.73 to 18.83 DID and from 0 na 34.23 DID, respectively; that of sequestrants decreased from 0.03 to 0.01 DID. Expenditures on fibrates showed a growth from 5.97 to 612.95 mil. CZK, those on statins from 0 to 1,772.25 mil. CZK, and those on sequestrants from 0.71 to 7.53 mil. CZK. In 1989, the proportion of fibrates, statins, and sequestrants in total hypolipidaemics utilization was 96%, 0%, and 4%, respectively; in 2003, it was 35%, 65%, and near to zero, respectively. In the beginning of the followed period, the utilization of hypolipidaemics in the Czech Republic was much lower than that in Western Europe. The situation changed in 1992, since when increasing trends both in utilization of and expenditures on hypolipidaemics can be seen.

Keywords: Key words: drug utilization, drug expenditures, hypolipidaemics, statins, fibrates.

Published: January 1, 2006  Show citation